Will3.jpg

Tim Miller
VP Platform Strategy
Thomson Reuters

Andrew Garrow
Director
CDF Solutions

William T Loging, Ph.D.
Head of Production Bioinformatics
Associate Professor of Genetics
Institute for Genomics and Multiscale Biology,
Icahn School of Medicine at Mount Sinai Hospital 

Dr. Anka G. Ehrhardt
Director, Clinical Flow Cytometry,
Bristol-Myers Squibb

Tim Miller
Vice President, Platform Strategy

Tim Miller has worked within the Thomson organization for over 30 years.  After 5 years in editorial for Derwent World Patents Index he moved to Product Development where he was responsible for a number of new products including GENESEQ, Patents Preview, Patents Citation Index, Derwent Chemistry Resource and Derwent Discovery.  In 2000 Tim transferred to IT where he architected and programme-managed a number of major infrastructure projects and led the IT integration of several acquisitions. In his current role Tim is responsible for the Life Sciences platform, focusing on developing new ways for our customers to derive additional value from our content, including enhancements to the Cortellis Web Portal, Web Services APIs, informatics and visualisation technologies. Tim holds a bachelor’s degree in Chemistry from the University of York and a bachelor’s degree in Law from the University of London.  He is a Chartered Chemist (Member of the Royal Society of Chemistry) and a Chartered Information Technology Professional (Member of the British Computer Society)


Andrew Garrow
Director

Andrew Garrow is a Data Scientist in the Thomson Reuters IP & Science Division.  Currently, Andrew is focused on Thomson Reuters Cortellis Data Fusion (CDF), a data integration solution powered by a unique hybrid of big data and semantic technologies.  Before working on CDF, Andrew developed capabilities to text mine clinical data in Cortellis and methodologies for mining social media for pharma relevant information.

Prior to joining Thomson Reuters, Andrew spent 5 years at Unilever working in a toxicology modelling and informatics group and completed a PhD at the University of Leeds, developing machine learning algorithms to search biological sequence databases.

ABSTRACT: In this presentation, I am going to provide a series of use cases, demonstrating how we have used Cortellis Data Fusion to support customers with their data integration needs.  I will demonstrate how we can implement a complete end to end data solution, covering everything from data collection and cleanup, to indexing and integration, through to visualisation and analytics, all at big-data scale.  I will provide examples of some of our visualisations and analytic tools, showing how we design solutions focusing on addressing key business objectives faced across the life sciences and pharma industries.


William T Loging, Ph.D.
 Head of Production Bioinformatics
Associate Professor of Genetics

Dr. Loging has spent the past 20 years focusing on generating treatments for human disease. Bridging both clinical genomics and pharmaceutical sciences, he has been globally recognized for his work with Maraviroc (Selzentry™) for use in HIV. The results of his contribution to the approval of Empagliflozin (Jardiance™) were listed within the drug insert. He has been published in several leading scientific journals on the utilization of novel informatic approaches to Drug Discovery and his TEDx talk last year on Cancer genomics was highly acclaimed. He currently holds several appointments at the Mt Sinai School of Medicine where he focuses on the clinical fields of Oncology and Immunology. 

ABSTRACTS: Technology advancements within the life sciences field have been unprecedented in the history of humankind. No place has this had more of an impact than in disease clinical assessment and drug discovery. We provide a comprehensive overview of the current paradigm of genome sequencing advancements to drug discovery and focus on use and application of Computational Biology approaches at the later stages of clinical trials. Novel computational aspects are highlighted along with an explanation that the current drug discovery archetypes need to change as the technology is changing. A focus on data visualization is also presented from both an internal, as well as external, perspective to discovery.